Canada’s Stem Cell Network made its first direct company investment, awarding $1 million to Montreal-based RejuvenRx through a new Incubation Investment Award. The program targets an early-stage funding gap between scientific proof and the capital needed for clinical development, manufacturing, and private investment. RejuvenRx is developing an oral medicine intended to restore healthy blood-forming stem cells and rebuild immune function, building on scientific work tied to UM171 at Université de Montréal. The award aims to help the company generate evidence and intellectual property to support later financing and scaling within Canada. The milestone highlights how national platforms are attempting to reduce capital discontinuities that can otherwise delay or relocate translational programs.